Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV

被引：51

作者：

Li, Shu-ren ^{[1
]}

Tang, Zi-jian ^{[1
,2
]}

Li, Zai-han ^{[3
]}

Liu, Xuan ^{[4
]}

机构：

[1] Hebei Gen Hosp, Shijiazhuang 050051, Hebei, Peoples R China

[2] Hebei Med Univ, Grad Sch, Hebei Gen Hosp, Shijiazhuang 050000, Hebei, Peoples R China

[3] Suzhou Univ, Suzhou 215000, Jiangsu, Peoples R China

[4] Hebei Med Univ, Hosp 4, Shijiazhuang 050000, Hebei, Peoples R China

来源：

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES | 2020年 / 39卷 / 06期

关键词：

New coronavirus (COVID-19); Angiotensin-converting enzyme 2 (ACE2); SARS coronavirus (SARS-CoV); ACE2;

D O I：

10.1007/s10096-020-03883-y

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Since December 2019, the infection of the new coronavirus (COVID-19) caused an outbreak of new coronavirus pneumonia in Wuhan, China, and caused great public concern. Both COVID-19 and SARS-CoV belong to the coronavirus family and both invade target cells through ACE2. An in-depth understanding of ACE2 and a series of physiological and physiological changes caused by the virus invading the human body may help to discover and explain the corresponding clinical phenomena and then deal with them timely. In addition, ACE2 is a potential therapeutic target. This article will summarize the role of ACE2 in multiple organ damage caused by COVID-19 and SARS-CoV, targeted blocking drugs against ACE2, and drugs that inhibit inflammation in order to provide the basis for subsequent related research, diagnosis and treatment, and drug development.

引用

页码：1021 / 1026

页数：6

共 33 条

[1]

[Anonymous], Nature

[2] Protease-Activated Receptor 1 Contributes to Angiotensin II-Induced Cardiovascular Remodeling and Inflammation [J].

Antoniak, Silvio ;

Cardenas, Jessica C. ;

Buczek, Laura J. ;

Church, Frank C. ;

Mackman, Nigel ;

Pawlinski, Rafal .

CARDIOLOGY, 2017, 136 (04) :258-268

[3]

Chai X, 2020, bioRxiv, DOI [10.1101/2020.02.03.931766, 10.1101/2020.02.03.931766]

[4] Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [J].

Chen, Nanshan ;

Zhou, Min ;

Dong, Xuan ;

Qu, Jieming ;

Gong, Fengyun ;

Han, Yang ;

Qiu, Yang ;

Wang, Jingli ;

Liu, Ying ;

Wei, Yuan ;

Xia, Jia'an ;

Yu, Ting ;

Zhang, Xinxin ;

Zhang, Li .

LANCET, 2020, 395 (10223) :507-513

[5] A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9 [J].

Donoghue, M ;

Hsieh, F ;

Baronas, E ;

Godbout, K ;

Gosselin, M ;

Stagliano, N ;

Donovan, M ;

Woolf, B ;

Robison, K ;

Jeyaseelan, R ;

Breitbart, RE ;

Acton, S .

CIRCULATION RESEARCH, 2000, 87 (05) :E1-E9

[6]

Fan C, 2020, 20022418 MEDRXIV

[7] Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease [J].

Ferrario, Carlos M. ;

Mullick, Adam E. .

PHARMACOLOGICAL RESEARCH, 2017, 125 :57-71

[8] Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2 [J].

Ferrario, CM ;

Jessup, J ;

Chappell, MC ;

Averill, DB ;

Brosnihan, KB ;

Tallant, EA ;

Diz, DI ;

Gallagher, PE .

CIRCULATION, 2005, 111 (20) :2605-2610

[9] ACE2 Activation Promotes Antithrombotic Activity [J].

Fraga-Silva, Rodrigo A. ;

Sorg, Brian S. ;

Wankhede, Mamta ;

deDeugd, Casey ;

Jun, Joo Y. ;

Baker, Matthew B. ;

Li, Yan ;

Castellano, Ronald K. ;

Katovich, Michael J. ;

Raizada, Mohan K. ;

Ferreira, Anderson J. .

MOLECULAR MEDICINE, 2010, 16 (5-6) :210-215

[10] Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor [J].

Han, Dong P. ;

Penn-Nicholson, Adam ;

Cho, Michael W. .

VIROLOGY, 2006, 350 (01) :15-25

← 1 2 3 4 →